ACRS Aclaris Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.69

Period return

+1.16 (+25.61%)

Volume

1.3M

2026-07-21O $5.55 H $5.69 L $5.46 C $5.69MA5 $5.58MA20 $5.38MA60 $4.81MA120 $4.21

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 06.LowBUY3 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 05. 05.MediumBUY3 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 04. 16.MediumBUY3 months ago
Oppenheimer: Outperform
US analyst rating / recommendation change.
2026. 03. 31.LowBUY4 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 03. 19.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 28.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 21.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $9.67 · 9 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
HQ: Wayne, PA, United States
Fiscal year end

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.16	—	—	$1.38M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.12	—	—	$1.46M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.5	—	—	$9.51M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.39	—	—	$5.16M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	574,213	$1.73M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	395,637	$1.48M	0.00%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	87,175	$262.4K	0.00%	—	New position

Aclaris Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 06.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 05. 05.	Guggenheim	—	Initiate coverage	— → Buy	—	Guggenheim: Buy
2026. 04. 30.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 04. 16.	Oppenheimer	—	Initiate coverage	— → Outperform	—	Oppenheimer: Outperform
2026. 03. 31.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 03. 19.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy